Alexander Cumbo, the President and CEO of $SLDB, sold 16,644 shares of the company on 02-18-2026 for an estimated $96,923. We received data on the trade from a recent SEC filing. This was a sale of approximately 6.6% of their shares of this class of stock. Following this trade, they now own 235,405 shares of this class of $SLDB stock.
$SLDB Insider Trading Activity
$SLDB insiders have traded $SLDB stock on the open market 29 times in the past 6 months. Of those trades, 0 have been purchases and 29 have been sales.
Here’s a breakdown of recent trading of $SLDB stock by insiders over the last 6 months:
- ALEXANDER CUMBO (President and CEO) has made 0 purchases and 4 sales selling 156,623 shares for an estimated $983,857.
- DAVID T HOWTON (Chief Operating Officer) has made 0 purchases and 4 sales selling 69,066 shares for an estimated $433,538.
- KEVIN TAN (CFO & Treasurer) has made 0 purchases and 4 sales selling 52,728 shares for an estimated $329,506.
- JESSIE HANRAHAN (Chief Regulatory Officer) has made 0 purchases and 4 sales selling 47,500 shares for an estimated $297,329.
- GABRIEL BROOKS (Chief Medical Officer) has made 0 purchases and 4 sales selling 43,846 shares for an estimated $280,914.
- PAUL HERZICH (Chief Technology Officer) has made 0 purchases and 4 sales selling 43,472 shares for an estimated $274,076.
- ILAN GANOT has made 0 purchases and 5 sales selling 14,385 shares for an estimated $82,374.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SLDB Hedge Fund Activity
We have seen 49 institutional investors add shares of $SLDB stock to their portfolio, and 69 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTAL POINT CAPITAL, LP added 2,840,000 shares (+95.5%) to their portfolio in Q4 2025, for an estimated $16,017,600
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,729,484 shares (-40.6%) from their portfolio in Q3 2025, for an estimated $16,840,916
- ARMISTICE CAPITAL, LLC added 1,676,000 shares (+179.1%) to their portfolio in Q4 2025, for an estimated $9,452,640
- MPM BIOIMPACT LLC removed 1,634,569 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $9,218,969
- MONASHEE INVESTMENT MANAGEMENT LLC added 1,349,771 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,612,708
- POINT72 ASSET MANAGEMENT, L.P. added 1,083,103 shares (+81.3%) to their portfolio in Q4 2025, for an estimated $6,108,700
- FMR LLC removed 884,229 shares (-30.3%) from their portfolio in Q4 2025, for an estimated $4,987,051
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SLDB Analyst Ratings
Wall Street analysts have issued reports on $SLDB in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 12/04/2025
- JP Morgan issued a "Overweight" rating on 11/05/2025
To track analyst ratings and price targets for $SLDB, check out Quiver Quantitative's $SLDB forecast page.
$SLDB Price Targets
Multiple analysts have issued price targets for $SLDB recently. We have seen 5 analysts offer price targets for $SLDB in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Gil Blum from Needham set a target price of $16.0 on 02/09/2026
- Anupam Rama from JP Morgan set a target price of $11.0 on 11/05/2025
- Yigal Nochomovitz from Citigroup set a target price of $14.0 on 11/05/2025
- Gena Wang from Barclays set a target price of $9.0 on 11/04/2025
- Geulah Livshits from Chardan Capital set a target price of $15.0 on 11/04/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
